9:59 AM
 | 
May 16, 2018
 |  BC Extra  |  Financial News

EIP gets $20.5M to develop AD candidate

CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million in a series B round led by new investor Access Industries. Other individual investors participated.

EIP told BioCentury it expects the funding to last through 2019. The company is enrolling 150 patients in the Phase IIb REVERSE-SD trial evaluating neflamapimod to treat Alzheimer's disease. Data are due in 2H19.

EIP licensed neflamapimod from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in 2014. The candidate aims to allay the inflammatory effects of plaque in AD by inhibiting P38 mitogen-activated protein kinase (p38 MAPK; MAPK14), which is expressed in the microglia and astrocytes where it regulates inflammation.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD